UCL

TODAQ Micro Launches Micropayments and AI Conversational Checkout

Retrieved on: 
Tuesday, April 2, 2024
CIO, CDO, UCL, Recess (album), Coalition, Digital, Patient, HHS, ARM, AI, Privacy, University College London, Music, Language, TAPP, Online shopping

Toronto, Ontario, April 02, 2024 (GLOBE NEWSWIRE) -- TODAQ Micro Inc. (“TODAQ”), a micropayments pioneer, is announcing the public beta launch of TAPPTM (Tap-and-Privately-Pay) and TAPP Conversational CheckoutTM AI sales agents. TAPP is a low-code software payment product that enables instant, “one-TAPP” payments for content or services without requiring a subscription sign-up or account log-in from the customer.

Key Points: 
  • Over 100 companies are adopting the company’s pay-as-you-go one-TAPP instant payment checkout solution for digital content and services, without users needing to subscribe or login
    Toronto, Ontario, April 02, 2024 (GLOBE NEWSWIRE) -- TODAQ Micro Inc. (“TODAQ”), a micropayments pioneer, is announcing the public beta launch of TAPPTM (Tap-and-Privately-Pay) and TAPP Conversational CheckoutTM AI sales agents.
  • TAPP Conversational Checkout is a first in the AI market.
  • Historically, a $0.25 payment could easily cost $0.35 to process, rendering a segment of potential customers uneconomical to serve,” said Hassan Khan, CEO of TODAQ.
  • “This kind of instant checkout experience otherwise has only been available through Apple, Amazon, or other tech giants.

UCLOUDLINK GROUP INC. Files 2023 Annual Report on Form 20-F

Retrieved on: 
Thursday, March 28, 2024
American depositary receipt, Annual report, Bank statement, UCL, Cryptocurrency

HONG KONG, March 28, 2024 (GLOBE NEWSWIRE) -- UCLOUDLINK GROUP INC. (“UCLOUDLINK” or the “Company”) (NASDAQ: UCL), the world’s first and leading mobile data traffic sharing marketplace, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (the “SEC”) on March 28, 2024.

Key Points: 
  • HONG KONG, March 28, 2024 (GLOBE NEWSWIRE) -- UCLOUDLINK GROUP INC. (“UCLOUDLINK” or the “Company”) (NASDAQ: UCL), the world’s first and leading mobile data traffic sharing marketplace, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (the “SEC”) on March 28, 2024.
  • The annual report can be accessed on UCLOUDLINK’s investor relations website at https://ir.ucloudlink.com .
  • The Company will also provide a hard copy of the annual report containing its audited consolidated financial statements, free of charge, to its shareholders and American Depositary Share holders upon request.
  • Requests should be directed to the Company’s Investor Relations Department at [email protected] .

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Retrieved on: 
Thursday, March 14, 2024
Nucleus, Bone marrow, BCMA, BioNTech, B-ALL, Patient, ALL, SLE, Engineering, Minocycline, European Medicines Agency, Therapy, Research, Canadian Aviation Regulations, Flow cytometry, ASH, General counsel, Immunotherapy, SVP, EMA, Legal Affairs, Trial of the century, GMP, SME, BLA, Nature Communications, Development, UCL, Biologics license application, Multiple myeloma, MIA, University College London, Senior, TRBC, GD2, ASCO, FDA, CD19, Conference call, Conference, MAA, EHA, ADS, MHRA, T cell, ACS Chemical Biology, PDUFA, Autoimmune disease, Pharmaceutical industry

“For now, we remain fully focused on preparing for a potential obe-cel launch and successfully transitioning Autolus to a commercial stage company.

Key Points: 
  • “For now, we remain fully focused on preparing for a potential obe-cel launch and successfully transitioning Autolus to a commercial stage company.
  • In February 2024, Autolus promoted Dr. Chris Williams to Chief Business Officer and Alex Driggs to Senior Vice President, Legal Affairs and General Counsel.
  • Dr. Leiderman brings extensive transactional and financial expertise, and Mr. Azelby brings more than 30 years of biopharmaceutical leadership and commercial experience to Autolus’ Board.
  • Financial Results for the Year Ended December 31, 2023

UCLOUDLINK GROUP INC. Announces Unaudited Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 14, 2024
Research, OTA, Software as a service, UCL, Platform as a service, Growth, Internet of things, COVID-19, ESIM, SIM, Travel, Internet, GMI, ADS, CPE, Depreciation, GAAP, Marketing, Total, Video game

Loss from operations was US$1.9 million, compared to a loss from operations of US$1.1 million in the fourth quarter of 2022.

Key Points: 
  • Loss from operations was US$1.9 million, compared to a loss from operations of US$1.1 million in the fourth quarter of 2022.
  • Net loss was US$1.8 million, compared to a net loss of US$1.1 million in the fourth quarter of 2022.
  • Adjusted EBITDA (non-GAAP) was US$1.5 million, compared to an adjusted EBITDA of US$1.6 million in the fourth quarter of 2022.
  • During the fourth quarter of 2023, 47.0% of daily active terminals were from uCloudlink 2.0 local data connectivity services and 53.0% of daily active terminals were from uCloudlink 1.0 international data connectivity services.

Remarkable College Offers Arrive for Concordia International School Shanghai Class of 2024

Retrieved on: 
Thursday, March 14, 2024
University, UCL, Sport, G5, Ivy League, Concordian International School, News, QS, Cornell University, University of Cambridge, Student, Biology, Concordia International School Shanghai, School, Economics, Engineering, Babson College, Berklee College of Music, Management

SHANGHAI, March 14, 2024 /PRNewswire/ -- The Class of 2024 at Concordia International School Shanghai has demonstrated exceptional global achievements in this year's university admission season.

Key Points: 
  • SHANGHAI, March 14, 2024 /PRNewswire/ -- The Class of 2024 at Concordia International School Shanghai has demonstrated exceptional global achievements in this year's university admission season.
  • This year, Concordia's college acceptance rates rank among the highest of international schools in Shanghai, showcasing the students' dedication and Concordia's unwavering commitment to excellence.
  • Concordia International School Shanghai supports its high school students with comprehensive counseling services from grades 9-12, focusing on academic, social-emotional, career, as well as global perspective and identity development.
  • Congratulations to the remarkable seniors of Concordia International School Shanghai.

UCLOUDLINK GROUP INC. to Report Fourth Quarter and Full Year 2023 Financial Results on March 14, 2024

Retrieved on: 
Thursday, March 7, 2024
UCL

HONG KONG, March 07, 2024 (GLOBE NEWSWIRE) -- UCLOUDLINK GROUP INC. (“UCLOUDLINK” or the “Company”) (NASDAQ: UCL), the world’s first and leading mobile data traffic sharing marketplace, today announced that it will report its unaudited financial results for the fourth quarter and full year of 2023 before U.S. markets open on Thursday, March 14, 2024.

Key Points: 
  • HONG KONG, March 07, 2024 (GLOBE NEWSWIRE) -- UCLOUDLINK GROUP INC. (“UCLOUDLINK” or the “Company”) (NASDAQ: UCL), the world’s first and leading mobile data traffic sharing marketplace, today announced that it will report its unaudited financial results for the fourth quarter and full year of 2023 before U.S. markets open on Thursday, March 14, 2024.
  • Management will hold a conference call to discuss these results at 8:30 a.m. Eastern Time / 8:30 p.m. Beijing Time the same day.
  • Listeners may access the call by dialing:

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Retrieved on: 
Tuesday, March 5, 2024
Axonal transport, Tauopathy, Neuron, CRVO, Cell biology, DLB, Plasma, Medical laboratory, MB, Phosphorylation, Overalls, FTD, GS, Vrije Universiteit Amsterdam, Publication, MAPK, Glial fibrillary acidic protein, GFAP, Axon, Brain, CNR, IW, EM, SDL, UCL, RAF kinase, Alpha-synuclein, Conference, Biomarker, AG, Lewy body, GBA, MD, Neurochemistry, PDF, JC, CP, Patient, Dementia, Basal forebrain, JA, Medical imaging

BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced the presentation of biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies (DLB), demonstrating that neflamapimod reduces plasma levels of glial fibrillary acidic protein (GFAP) compared placebo, and that the effects of neflamapimod on GFAP were inversely correlated to change in CDR-SB (reduction in GFAP associated with improvement in CDR-SB, and increase in GFAP associated with worsening in CDR-SB). These data will be featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024, being held both virtually and in Lisbon, Portugal from March 5–9, 2024. In addition, academic researchers from UCL will be presenting data in a separate poster at the meeting demonstrating that p38MAPK inhibition, including with neflamapimod specifically, improves tau-induced axonal transport defects both in vitro and in a tauopathy mouse model.

Key Points: 
  • These data will be featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024, being held both virtually and in Lisbon, Portugal from March 5–9, 2024.
  • “The effects on GFAP, particularly the association between GFAP response and clinical outcomes, further support that neflamapimod is clinically efficacious in patients with DLB,” said John Alam, MD, Chief Executive Officer of CervoMed.
  • A PDF copy of the GFAP poster presentation will be available on the “ Presentations and Publications ” section of the CervoMed website.
  • Title: NEW INSIGHTS IN THE DEVELOPMENT OF BIOMARKERS, IMAGING, AND THERAPY OF ALPHA-SYNUCLEIN, LRKK2, AND GBA PATHOLOGIES

Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure

Retrieved on: 
Tuesday, February 27, 2024
Interventional oncology, University College London, Division, FRCS, Magnetic resonance, Prostate cancer, MD, Temperature, UCL, TSX, Surgeon, BPH, Prostate, Patient, Helium, Diagnosis, Deep learning, Claustrophobia, Workflow, Siemens Healthineers, MRI, Cancer, Partnership, Medical imaging

TULSA is a “one-and-done” procedure, performed in a single session that takes a few hours, and no hospital stay is required.

Key Points: 
  • TULSA is a “one-and-done” procedure, performed in a single session that takes a few hours, and no hospital stay is required.
  • At less than 7,700 Lbs and 80 inches high, MAGNETOM Free.Max is the most lightweight, compact whole-body scanner ever offered by Siemens Healthineers.
  • I commend the teams at Siemens Healthineers and Profound as they work to achieve the convergence of their respective diagnostic and interventional MR technologies.
  • We look forward to collaborating with Profound to help expand access to TULSA as well.

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Retrieved on: 
Wednesday, March 6, 2024
Senior, Research, SAB, Lecanemab, Clinical Chemistry (journal), Neuroimaging, Lund University, University, Associate, Henrik, Key, School, OGA, Principal, Research and development, Queen Silvia of Sweden, Young, Brain, Therapy, Pharmacology, SAN, UCL, Geriatric psychiatry, Eric, Biomarker, Yale School of Medicine, ACTC, Sahlgrenska University Hospital, University College London, Division, Neurochemistry, FDA, Public health, Phase II, Neurology, Senior advisor, Executive Committee, Patient, Cognition, Yale school, European Grand Prix, Biogen, Pharmaceutical industry

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).

Key Points: 
  • LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).
  • Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease.
  • The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development.
  • I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development.

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Retrieved on: 
Wednesday, March 6, 2024
Senior, Research, SAB, Lecanemab, Clinical Chemistry (journal), Neuroimaging, Lund University, University, Associate, Henrik, Key, School, OGA, Principal, Research and development, Queen Silvia of Sweden, Young, Brain, Therapy, Pharmacology, SAN, UCL, Geriatric psychiatry, Eric, Biomarker, Yale School of Medicine, ACTC, Sahlgrenska University Hospital, University College London, Division, Neurochemistry, FDA, Public health, Phase II, Neurology, Senior advisor, Executive Committee, Patient, Cognition, Yale school, European Grand Prix, Biogen, Pharmaceutical industry

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).

Key Points: 
  • LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).
  • Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease.
  • The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development.
  • I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development.